- Conditions
- Neuroendocrine Carcinoma
- Interventions
- Avastin, RAD001
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 11,702
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pre-surgical Treatment with Bevacizumab plus Chemotherapy, Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
- Interventions
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo
- Biological · Other
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Malignant Neoplasms of Respiratory and Intrathoracic Organs, Squamous Cell Carcinoma of the Larynx
- Interventions
- Stereotactic Hypofractionated Radioablation, Questionnaires
- Radiation · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- IPI-504, Everolimus
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Tampa, Florida • Boston, Massachusetts + 1 more
- Conditions
- Squamous Cell Carcinoma
- Interventions
- Azacitidine, Cisplatin
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma
- Interventions
- CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
- Drug
- Lead sponsor
- Cytovation AS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Duarte, California • Detroit, Michigan + 3 more
- Conditions
- Cervical Cancer, Vaginal Cancer
- Interventions
- therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 64 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 51
- States / cities
- Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more
- Conditions
- Breast Neoplasms
- Interventions
- accelerated partial breast irradiation
- Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pancreatic Cancer
- Interventions
- Cabozantinib, Pembrolizumab
- Drug
- Lead sponsor
- Joseph Kim
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Carcinoma, Pancreatic Delta Cell Carcinoma, Pancreatic G-cell Carcinoma, Recurrent Islet Cell Carcinoma
- Interventions
- temozolomide, pazopanib hydrochloride
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more
- Conditions
- Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
- Interventions
- IPI-549 (eganelisib), Nivolumab
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 11
- States / cities
- San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more
- Conditions
- Kidney Cancer
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Carboplatin, Pembrolizumab, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
- Drug · Biological · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Adenoid Cystic Carcinoma
- Interventions
- AG-013736 (AXITINIB)
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Renal Cell Carcinoma (aRCC)
- Interventions
- Nivolumab + Ipilimumab combination therapy, Pembrolizumab + Lenvatinib combination therapy
- Combination Product
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Dublin, Ohio
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib, Survey Administration, Telisotuzumab Vedotin
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Tocilizumab, Transcatheter Arterial Chemoembolization
- Drug · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Head and Neck Carcinoma
- Interventions
- Electronic Health Record Review, Exercise Intervention, Medical Device Usage and Evaluation, Survey Administration
- Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab, Osimertinib, Lazertinib, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,074 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 20
- States / cities
- Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more
- Conditions
- Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
- Interventions
- PBA-0111
- Drug
- Lead sponsor
- Pure Biologics S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- Advanced Solid Tumors
- Interventions
- PX-866
- Drug
- Lead sponsor
- Cascadian Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Houston, Texas